ArticleFrontiers in pharmacology2025
Identification of gene signatures and potential pharmaceutical candidates linked to COVID-19-related depression based on gene expression profiles.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute and long-term mental health disorders correlate with coronavirus disease 2019 (COVID-19). The underlying mechanisms responsible for the coexistence of COVID-19 and depression remain unclear, and more research is needed to find hub genes and effective therapies. The main objective of this study was to evaluate gene-expression profiles and, identify key genes, and discovery potential therapeutic agents for co-occurrence in COVID-19 and major depressive disorder (MDD). Methods: Initially, we identified differentially expressed genes (DEGs) in datasets from COVID-19 (GSE188847) or MDD (GSE101521). Subsequently, we employed two machine learning analyses-least absolute shrinkage and selection operator (LASSO) and random forest algorithms- to pinpoint shared hub gene between the two diseases. Furthermore, the LINCS L1000 characteristic direction signatures search engine (L1000CDS2) was utilized for drug repurposing studies based on the gene-expression signatures. Finally, molecular dynamics (MD) simulations were conducted to investigate the binding interactions between molecules and the target proteins. Results: We uncovered 60 DEGs that overlapped between the two datasets but exhibited distinct patterns of expression in each dataset. Subsequent machine learning analyses revealed EMILIN3, OPA3, and TFCP2 as potential shared hub genes underlying both diseases. Furthermore, L1000CDS2 analysis indicated that trichostatin A (TSA), a metabolite derived from Streptomyces, could potentially reverse the altered gene expression. Molecular docking and molecular dynamics simulations revealed that complexes of TSA-perturbed protein spontaneously form and are highly stable. Conclusion: EMILIN3, OPA3, and TFCP2 are likely to be potential shared hub genes in both COVID-19 and depression. Meanwhile, TSA may serve as a therapeutic option for treating COVID-19-associated depression. Given the inherent constraints of computational modeling, further biological validation studies would help establish the significance of these preliminary findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.